Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Femoxetine and amitriptyline in general practice: a randomized double-blind group comparison.

B K Skrumsager, K Jeppesen

    Pharmacopsychiatry
    |September 1, 1986
    PubMed
    Summary

    This study found that femoxetine and amitriptyline showed similar effectiveness for major depressive disorder over six weeks. Amitriptyline had a faster initial effect on sleep symptoms, but both drugs had comparable dropout rates due to side effects.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes.

    Journal of clinical pharmacology·2003
    Same author

    Pharmacokinetics of levormeloxifene in young versus elderly postmenopausal women.

    Clinical therapeutics·2001
    Same author

    Tolerability, safety and pharmacokinetics of single dose and multiple dosing of the selective D1 antagonist NNC 01-0687 in healthy subjects.

    Psychopharmacology·1995
    Same author

    NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia.

    Psychopharmacology·1995
    Same author

    A tolerance study of single and multiple dosing of the selective dopamine uptake inhibitor GBR 12909 in healthy subjects.

    International clinical psychopharmacology·1990
    Same author

    Cardiovascular (ECG and systolic time intervals) and anticholinergic effects of repeated doses of femoxetine--a comparison with amitriptyline and placebo in healthy men.

    British journal of clinical pharmacology·1989

    Area of Science:

    • Psychiatry
    • Clinical Pharmacology

    Background:

    • Major depressive disorder (MDD) is a prevalent mental health condition requiring effective treatment options.
    • Selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs) are common pharmacological approaches.

    Purpose of the Study:

    • To compare the efficacy and tolerability of femoxetine (an SSRI) versus amitriptyline (a TCA) in patients with definite major depressive disorder.
    • To assess treatment outcomes using the Hamilton Depression Scale (HDS) and clinical global assessment.

    Main Methods:

    • A randomized, double-blind, group comparative study involving 81 patients diagnosed with definite major depressive disorder.
    • Patients received either 600 mg daily of femoxetine or 150 mg daily of amitriptyline for six weeks.
    • Efficacy was measured by HDS scores and global assessments; side effects and dropout rates were also recorded.

    Related Experiment Videos

    Main Results:

    • No statistically significant differences in overall efficacy were observed between femoxetine and amitriptyline after six weeks.
    • Amitriptyline demonstrated a significantly greater reduction in HDS sleep item scores at week 2.
    • Dropout rates due to side effects were similar (14-15%), though femoxetine had fewer reported side effects overall (38% vs. 14%).

    Conclusions:

    • Femoxetine and amitriptyline exhibit comparable overall efficacy for major depressive disorder in general practice settings over a six-week period.
    • Amitriptyline may offer a faster onset of action, particularly concerning sleep disturbances.
    • Both treatments present distinct side effect profiles, with femoxetine associated with nausea and amitriptyline with anticholinergic effects; femoxetine did not cause weight gain.